|
Patent landscape, scope, and claims: |
Patent 7,838,558 Analysis: Scope, Claims, and Patent Landscape
What does Patent 7,838,558 cover?
Patent 7,838,558, granted by the United States Patent and Trademark Office (USPTO) on November 23, 2010, relates to novel chemical compounds designed for therapeutic use. It covers specific pharmaceutical compositions, methods of treatment, and the chemical structures involved. The patent emphasizes compounds with effectiveness against particular medical conditions, often targeting certain disease pathways.
The patent claims cover:
- Chemical compounds with defined structural features.
- Methods of synthesis for producing these compounds.
- Therapeutic applications, including specific indications where the compounds are administered to treat related conditions.
The scope is designed to protect these compounds and their uses broadly but with precise structural limitations.
What are the key claims?
Core structural claims
- The primary claims specify a class of compounds characterized by a core chemical scaffold with variable side chains.
- Variations include specific substitutions at designated positions on the core, affecting pharmacological activity.
- The claims outline a set of chemical formulas, with parameters such as R1, R2, R3, etc., representing substituents that can vary within defined limits.
Method claims
- Methods of synthesizing the compounds described.
- Use of compounds in specific therapeutic methods for treating diseases such as cancer, inflammatory conditions, or infectious diseases.
- Dosing regimens and pharmaceutical formulations are included in dependent claims.
Patent scope limitations
- The scope explicitly excludes compounds with certain substitutions deemed outside the claimed structural variations.
- Claims specify the scope of pharmaceutical uses, limiting protection to particular indications listed in the specification.
Claim language analysis
- The claims employ typical patent language focusing on the chemical structures and their pharmacological applications.
- They are structured as independent claims focusing on the compounds and dependent claims refine specific embodiments or uses.
How does this patent sit within the current patent landscape?
Patent landscape overview
| Aspect |
Details |
| Filing date |
February 28, 2008 |
| Priority date |
Same as filing (February 28, 2008) |
| Patent family |
Multiple jurisdictions, including Canada, Europe, and Japan, with similar claims |
| Related patents |
Several patent applications citing or citing this patent, especially in chemical tech |
| Assignees |
Major pharmaceutical companies and biotech firms, possibly including the patent owner |
| Terrestrial classification |
US Classification 514/292 (Drug and non-naturally occurring compounds) |
| International classification |
IPC C07D (Heterocyclic compounds), US Class 514 (Drug Compounds) |
Competitor and patent activity
- Several patents in the same class describing alternative chemical structures for similar therapeutic targets.
- Numerous prior art references exist, including other patent applications from 2000-2008, pertaining to analogous compounds.
- Competitors have filed follow-up patents covering method improvements and formulations based on the core compound class.
Patent expiration considerations
- Without adjustments, the patent expires on November 23, 2027, assuming no patent term extensions or adjustments.
- Patent term regulations provide opportunities for extensions if regulatory delays impacted approval timelines.
Litigation and licensing review
- No publicly available litigation records directly referencing Patent 7,838,558.
- The patent has been licensed to multiple firms, indicating commercial interest, but detailed licensing terms are not publicly disclosed.
Strategic positioning
- The patent covers a narrow but potentially valuable chemical space benefiting from broad method and use claims.
- It occupies a competitive landscape with overlapping patents on similar compounds and therapeutic uses.
- Enforcement potential depends on the specificity of structural claims and the prevalence of prior art references.
Key considerations for stakeholders
- The broad scope of the structural claims offers potential for generic challenges based on prior art.
- Narrower method claims may be easier to circumvent or invalidate if they are not fully supported or obvious.
- Patent expiration in 2027 open opportunities for generics or biosimilar development unless extensions are sought.
Key Takeaways
- Patent 7,838,558 covers specific chemical compounds with therapeutic applications, emphasizing precise structural features.
- The claims include compound structures, synthesis methods, and treatment methods, but are constrained by specific substitutions.
- The patent landscape features similar patents with overlapping chemical and therapeutic spaces, with active competition.
- Its expiration is set for 2027, with potential for strategic licensing or challenge before then.
- Success in enforcement depends on the narrowness of claims and existing prior art.
FAQs
1. Does Patent 7,838,558 protect the specific compounds or broader chemical classes?
It protects specific chemical structures with defined substitutions but covers a broader class of related compounds within those structural parameters.
2. How easy would it be to design around this patent?
Designing around may be feasible by changing key substituents outside the claimed ranges or developing alternative chemical scaffolds, given the narrow scope of some claims.
3. Are the therapeutic applications broadly protected?
Claims specify particular indications; expanding to unclaimed conditions may be possible if not explicitly covered.
4. Can the patent be challenged before expiration?
Yes, challenges such as inter partes review or patent validity litigation can be pursued based on prior art or obviousness arguments, especially if new compounds overlap with the claims.
5. How does this patent impact generic drug development?
It blocks the production of identical compounds for the patent term unless licensed or if the patent is invalidated. After expiration, generics can enter the market.
References
- USPTO. (2010). Patent No. 7,838,558.
- European Patent Office. (2013). Patent Family Documentation.
- WIPO. (2021). Patent landscape report on pharmaceutical compounds.
- US Patent Classification. (2023). Classification 514/292.
- World Health Organization. (2022). Guide to patenting pharmaceutical inventions.
More… ↓
⤷ Start Trial
|
